Commitments and Contingencies (Details) (USD $)	12 Months Ended
	Dec. 31, 2013		Dec. 31, 2012	Dec. 31, 2011
Operating leases, future cash payments [Abstract]
2014	$ 337,000	[1]
2015	258,000	[1]
2016	228,000	[1]
2017	255,000	[1]
Total	1,642,000	[1]
Lease expense	315,134		324,536	321,782
Employment agreements, future cash payments [Abstract]
2014	2,575,000	[2]
2015	850,000	[2]
Total	3,425,000	[2]
Subtotal, future cash payments due [Abstract]
2014	2,912,000
2015	1,108,000
2016	228,000
2017	255,000
Total	5,067,000
Research and development, future cash payments due [Abstract]
2014	8,490,000	[3]
2015	2,106,000	[3]
2016	943,000	[3]
2017	681,000	[3]
Total	12,220,000	[3]
Total, future minimum payments due [Abstract]
2014	11,402,000
2015	3,214,000
2016	1,171,000
2017	936,000
Total	$ 17,287,000

[1] Operating leases are primarily facility lease related obligations, as well as equipment lease obligations with third party vendors. The Company recognized lease expenses of $315,134, $324,536 and $321,782 in 2013, 2012 and 2011, respectively.

[2] Employment agreements include management contracts which have been revised from time to time. The employment agreement for the Company’s President and Chief Executive Officer provides for a minimum salary level, which is adjusted annually at the discretion of the Company’s Compensation Committee, as well as for minimum bonuses that are payable. New employment agreements for the Company’s other executive officers are usually entered into annually.

[3] Research and development obligations relate primarily to clinical trials. Most of these purchase obligations are cancelable.